stoxline Quote Chart Rank Option Currency Glossary
  
Zomedica Corp. (ZOM)
0.1503  0 (0.13%)    07-19 13:33
Open: 0.15
High: 0.152
Volume: 1,597,124
  
Pre. Close: 0.1501
Low: 0.15
Market Cap: 147(M)
Technical analysis
2024-07-19 1:24:05 PM
Short term     
Mid term     
Targets 6-month :  0.18 1-year :  0.19
Resists First :  0.15 Second :  0.16
Pivot price 0.14
Supports First :  0.14 Second :  0.11
MAs MA(5) :  0.15 MA(20) :  0.14
MA(100) :  0.14 MA(250) :  0.16
MACD MACD :  0 Signal :  -0.1
%K %D K(14,3) :  44.4 D(3) :  62.1
RSI RSI(14): 51.5
52-week High :  0.22 Low :  0.11
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.
[ ZOM ] has closed below upper band by 31.1%. Bollinger Bands are 48.2% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 11 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 0.17 - 0.17 0.17 - 0.17
Low: 0.15 - 0.15 0.15 - 0.15
Close: 0.15 - 0.15 0.15 - 0.15
Company Description

Zomedica Corp., a veterinary health company, focuses on the unmet needs of clinical veterinarians by developing products for companion animals. The company engages in the development and commercialization of TRUFORMA platform, which offers point-of-care diagnostic products for disease states in dogs and cats; and PulseVet, provides for treatment of various musculoskeletal issues, such as broken bones, tendonitis, and torn ligaments in horses and small animals. It has collaboration agreements with Celsee, Inc. for the development and commercialization of liquid biopsy assays and related consumables for the detection of cancer in companion animals; and Seraph Biosciences, Inc. for development and markets a novel pathogen detection system. The company was formerly known as Zomedica Pharmaceuticals Corp. and changed its name to Zomedica Corp. in October 2020. Zomedica Corp. was founded in 2015 and is headquartered in Ann Arbor, Michigan.

Headline News

Wed, 17 Jul 2024
The United States Eventing Association Names Zomedica’s PulseVet(R) as the Official Shock Wave of the USEA - StockTitan

Wed, 10 Jul 2024
Zomedica Expands Global Reach through Strategic Alliance with Leader Healthcare Group for Sales Expansion in Key International Markets - Marketscreener.com

Mon, 13 May 2024
Zomedica CEO Larry Heaton acquires $14k in company stock - Investing.com

Fri, 10 May 2024
Zomedica Corp (ZOM) Q1 2024 Earnings: Revenue Climbs Amidst Rising Costs, Aligns with Analyst ... - Yahoo Finance

Thu, 09 May 2024
Zomedica Reports Record Q1 Growth and Optimism - TipRanks

Thu, 09 May 2024
Zomedica Announces First Quarter 2024 Financial Results: Revenue up 14% to $6.3 Million; 66% Gross Margin, and $91 Million in Liquidity - AccessWire

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Underperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Outperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Underperform
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Neutral
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Neutral
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Neutral
Stock Basics & Statistics
Exchange:
AMEX
Sector:
Healthcare
Industry:
Drug Manufacturers - Specialty & Generic
Shares Out 980 (M)
Shares Float 964 (M)
Held by Insiders 1.5 (%)
Held by Institutions 8.5 (%)
Shares Short 63,430 (K)
Shares Short P.Month 62,890 (K)
Stock Financials
EPS -0.02
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0.27
Profit Margin -62.3 %
Operating Margin -93.8 %
Return on Assets (ttm) -5.7 %
Return on Equity (ttm) -5.7 %
Qtrly Rev. Growth 32.9 %
Gross Profit (p.s.) 0.01
Sales Per Share 0.02
EBITDA (p.s.) -0.03
Qtrly Earnings Growth 0 %
Operating Cash Flow -13 (M)
Levered Free Cash Flow -20 (M)
Stock Valuations
PE Ratio -7.56
PEG Ratio 0
Price to Book value 0.55
Price to Sales 6.16
Price to Cash Flow -11.1
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android